Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.

Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.

A high percentage of patients with the myeloproliferative disorder polycythemia vera (PV) harbor a Val617→Phe activating mutation in the Janus kinase 2 (JAK2) gene, and both cell culture and mouse models have established a functional role for this mutation in the development of this disease. We desc...

Full description

Bibliographic Details
Main Authors: Manfred Kraus, Yuxun Wang, Dan Aleksandrowicz, Eric Bachman, Alexander A Szewczak, Deborah Walker, Lin Xu, Melaney Bouthillette, Kaleen M Childers, Brian Dolinski, Andrew M Haidle, Johnny Kopinja, Linda Lee, Jongwon Lim, Kevin D Little, Yanhong Ma, Anjili Mathur, Jan-Rung Mo, Erin O'Hare, Ryan D Otte, Brandon M Taoka, Wenxian Wang, Hong Yin, Anna A Zabierek, Weisheng Zhang, Shuxia Zhao, Joe Zhu, Jonathan R Young, C Gary Marshall
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3356383?pdf=render

Similar Items

Similar Items